Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. more
Time Frame | NMRA | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.29% | -2.27% | -0.57% |
1-Month Return | -4.22% | -3.96% | 1.21% |
3-Month Return | -14.21% | -9.7% | 7.57% |
6-Month Return | 3.72% | -3.37% | 11.45% |
1-Year Return | -27.58% | 3.71% | 28.48% |
3-Year Return | -39.29% | 3.8% | 29.52% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | 1.55M | 2.70M | 668.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":57.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":24.77,"profit":true}] |
Gross Profit | - | - | (1.55M) | (2.70M) | (668.00K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-155100000,"profit":false},{"date":"2022-12-31","value":-269700000,"profit":false},{"date":"2023-12-31","value":-66800000,"profit":false}] |
Gross Margin | - | - | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | - | 95.52M | 237.32M | 135.87M | 187.53M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":40.25,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":57.25,"profit":true},{"date":"2023-12-31","value":79.02,"profit":true}] |
Operating Income | - | (95.52M) | (237.32M) | (135.87M) | (188.19M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-9551800000,"profit":false},{"date":"2021-12-31","value":-23732300000,"profit":false},{"date":"2022-12-31","value":-13587000000,"profit":false},{"date":"2023-12-31","value":-18819400000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | 11.00K | 9.53M | (30.85M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":0.12,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-323.84,"profit":false}] |
Pre-Tax Income | - | (99.27M) | (237.31M) | (130.90M) | (235.66M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-9927200000,"profit":false},{"date":"2021-12-31","value":-23731200000,"profit":false},{"date":"2022-12-31","value":-13090400000,"profit":false},{"date":"2023-12-31","value":-23565700000,"profit":false}] |
Income Taxes | - | (101.30K) | 301.44K | (4.56M) | 268.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-33.6,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-1513.06,"profit":false},{"date":"2023-12-31","value":88.91,"profit":true}] |
Income After Taxes | - | - | (237.61M) | (126.34M) | (235.93M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-23761344200,"profit":false},{"date":"2022-12-31","value":-12634300000,"profit":false},{"date":"2023-12-31","value":-23592500000,"profit":false}] |
Income From Continuous Operations | - | (99.27M) | (237.31M) | (130.90M) | (235.93M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-9927200000,"profit":false},{"date":"2021-12-31","value":-23731200000,"profit":false},{"date":"2022-12-31","value":-13090400000,"profit":false},{"date":"2023-12-31","value":-23592500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | - | (99.27M) | (237.31M) | (130.90M) | (235.93M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-9927200000,"profit":false},{"date":"2021-12-31","value":-23731200000,"profit":false},{"date":"2022-12-31","value":-13090400000,"profit":false},{"date":"2023-12-31","value":-23592500000,"profit":false}] |
EPS (Diluted) | - | - | - | - | (2.13) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-212.83,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
NMRA | |
---|---|
Cash Ratio | 10.75 |
Current Ratio | 10.98 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NMRA | |
---|---|
ROA (LTM) | -37.75% |
ROE (LTM) | -77.08% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NMRA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.09 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NMRA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 5.20 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Neumora Therapeutics, Inc. Common Stock (NMRA) share price today is $10.32
Yes, Indians can buy shares of Neumora Therapeutics, Inc. Common Stock (NMRA) on Vested. To buy Neumora Therapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NMRA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Neumora Therapeutics, Inc. Common Stock (NMRA) via the Vested app. You can start investing in Neumora Therapeutics, Inc. Common Stock (NMRA) with a minimum investment of $1.
You can invest in shares of Neumora Therapeutics, Inc. Common Stock (NMRA) via Vested in three simple steps:
The 52-week high price of Neumora Therapeutics, Inc. Common Stock (NMRA) is $21. The 52-week low price of Neumora Therapeutics, Inc. Common Stock (NMRA) is $8.33.
The price-to-earnings (P/E) ratio of Neumora Therapeutics, Inc. Common Stock (NMRA) is
The price-to-book (P/B) ratio of Neumora Therapeutics, Inc. Common Stock (NMRA) is 5.20
The dividend yield of Neumora Therapeutics, Inc. Common Stock (NMRA) is 0.00%
The market capitalization of Neumora Therapeutics, Inc. Common Stock (NMRA) is $1.70B
The stock symbol (or ticker) of Neumora Therapeutics, Inc. Common Stock is NMRA